After the four-month beta trial, Goldman and cofounder Corey Katz plan on launching in the European market with the ability to identify and analyze more molecules indicative of medical conditions in the population at large.
“I expect to see it actually go to the healthy people more than to the sick people,” he notes.
Users could range from athletes wanting to up their performance, to people at bars wanting to know their alcohol levels, to dieters.
As a runner, Goldman says he is “always looking for ways to improve my performance. But I have no idea what works for me and what doesn’t. It could be that when I run, I burn out all my potassium. I have no way of knowing this. But it could be that if I ate a banana before I run, then I’ll increase my performance because I have potassium during my run.”
Optics-based, at-home urinalysis has the potential to amass a lot of data about the user’s present and future health. The artificial intelligence component compares it to data from similar people to yield even sharper insights.
“To me, that is the soul of what we’re doing,” he says.
To ensure all this confidential data remains private and compliant with legal requirements such as GDPR and HIPAA, Olive will adapt its system for every country it enters. Olive Diagnostics’ initial funding comes from Cleveland Clinic, Amgen, Israeli Innovation Authority, eHealth Ventures and private investors.
“Urine is central to medicinal, health monitoring. Current solutions are cumbersome, limiting tracking analysis or medical history,” said Dr. Joseph Rosenblum, chief medical officer of eHealth Ventures. “People want convenient, at-home healthcare solutions, passive diagnostic tools, disease prevention, early detection, and accurate intervention, especially with rising healthcare costs and COVID.”
For more information, click here
To learn more:
Contact Guy Goldman, CEO of Olive Diagnostics at guy.goldman@olive.earth
For eHealth Ventures, contact ophir@ehv.health